GE

276.29

+0.12%↑

RTX

151.9

-1.32%↓

CAT

417.84

-1.1%↓

BA

229.49

-0.58%↓

GEV.US

605.48

+0.89%↑

GE

276.29

+0.12%↑

RTX

151.9

-1.32%↓

CAT

417.84

-1.1%↓

BA

229.49

-0.58%↓

GEV.US

605.48

+0.89%↑

GE

276.29

+0.12%↑

RTX

151.9

-1.32%↓

CAT

417.84

-1.1%↓

BA

229.49

-0.58%↓

GEV.US

605.48

+0.89%↑

GE

276.29

+0.12%↑

RTX

151.9

-1.32%↓

CAT

417.84

-1.1%↓

BA

229.49

-0.58%↓

GEV.US

605.48

+0.89%↑

GE

276.29

+0.12%↑

RTX

151.9

-1.32%↓

CAT

417.84

-1.1%↓

BA

229.49

-0.58%↓

GEV.US

605.48

+0.89%↑

Search

Ocugen Inc

Închisă

1.02

Rezumat

Modificarea prețului

24h

Curent

Minim

0.99

Maxim

1.03

Indicatori cheie

By Trading Economics

Venit

611K

-15M

Vânzări

-108K

1.4M

Marjă de profit

-1,073.489

Angajați

95

EBITDA

724K

-13M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+514.56% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

237K

319M

Deschiderea anterioară

1.02

Închiderea anterioară

1.02

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 sept. 2025, 23:59 UTC

Achiziții, Fuziuni, Preluări

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8 sept. 2025, 22:02 UTC

Principalele dinamici ale pieței

Microsoft Signs $17.4 Billion AI Deal With Nebius

8 sept. 2025, 17:01 UTC

Principalele dinamici ale pieței

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8 sept. 2025, 17:01 UTC

Principalele dinamici ale pieței

Tron Shares Rise After New Investment From Bravemorning

8 sept. 2025, 16:14 UTC

Principalele dinamici ale pieței

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8 sept. 2025, 16:13 UTC

Principalele dinamici ale pieței

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8 sept. 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8 sept. 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8 sept. 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8 sept. 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8 sept. 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8 sept. 2025, 21:47 UTC

Principalele dinamici ale pieței

Microsoft Signs $17.4B AI Deal With Nebius

8 sept. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8 sept. 2025, 21:20 UTC

Achiziții, Fuziuni, Preluări

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8 sept. 2025, 21:19 UTC

Achiziții, Fuziuni, Preluări

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8 sept. 2025, 21:18 UTC

Achiziții, Fuziuni, Preluări

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8 sept. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8 sept. 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8 sept. 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 sept. 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8 sept. 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8 sept. 2025, 16:59 UTC

Market Talk
Achiziții, Fuziuni, Preluări

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8 sept. 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8 sept. 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8 sept. 2025, 16:16 UTC

Câștiguri

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8 sept. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8 sept. 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

514.56% sus

Prognoză pe 12 luni

Medie 6.33 USD  514.56%

Maxim 8 USD

Minim 4 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat